Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

Threshold cancer news

January 4, 2016 8:00 AM UTC

Threshold will reduce headcount by about 66% to 20-25 to focus resources on two ongoing Phase II trials of tarloxotinib ( TH-4000) to treat non-small cell lung cancer (NSCLC) and squamous cell carcinomas of the head and neck or skin, respectively. Tarloxotinib is a hypoxia-activated irreversible EGFR and EGFR2 ( HER2; ErbB2; neu) tyrosine kinase inhibitor. Threshold has exclusive, worldwide rights to the compound from the University of Auckland (Auckland, New Zealand) under a 2014 deal. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article